Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and immune dysregulation. Despite the established link with immune function, the genetic and pathological mechanisms connecting immune-related genes to MS remain incompletely understood.
Methods: We systematically integrated genome-wide association study (GWAS) data for various quantitative trait loci (QTLs) from public databases and literature, along with GWAS summary statistics for MS from IMSGC and FinnGen. Mendelian Randomization (MR) was used to infer potential causal relationships between immune-related factors and MS. To validate whether the same genetic variants underlie both traits, Bayesian colocalization analysis was performed. Summary-data-based Mendelian Randomization (SMR) further supported causality between the exposure and outcome. Finally, two-step MR was conducted to investigate whether immune cell subsets mediate the observed associations.
Results: Fc receptor-like 3 (FCRL3) was identified as a protective factor for MS, supported by MR analyses at multiple levels: circulating protein (OR = 0.912, 95 % CI = 0.882-0.942), blood-derived gene expression (OR = 0.772, 95 % CI = 0.598-0.997), and cerebral cortex expression (OR = 0.573, 95 % CI = 0.455-0.721). Causality was further supported by SMR (pSMR = 5.38E-04; pHEIDI = 0.478) and Bayesian colocalization (PP.H₄ = 0.915). The protective effect of FCRL3 on MS was found to be partially mediated by CD3 expression on naïve CD4 T cells.
Conclusion: This study systematically evaluated the causal roles of immune-related genes in MS susceptibility and identified FCRL3 as a protective factor. These findings underscore the significance of FCRL3 in MS pathogenesis and suggest its potential as a target for future immunotherapeutic strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2025.120174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural Products for Regulation of Autoimmune Diseases: Chemical Diversity, Pharmacology, and Therapeutic Applications.
Chem Biodivers
September 2025
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.
View Article and Find Full Text PDFIncidence, Etiology, and Long-Term Outcome of Acute Myelitis in Stockholm County, Sweden: A Population-Based Study.
Neurol Neuroimmunol Neuroinflamm
November 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Background And Objectives: Myelitis is a relatively common clinical entity for neurologists, with diverse underlying causes. The aim of this study was to describe the incidence of myelitis, its causes, clinical presentation, and factors predicting functional outcomes and relapses.
Methods: Using the Swedish National Patient Registry, we identified all adult patients in Stockholm County between 2008 and 2018 using International Classification of Diseases, 10th Edition (ICD-10) codes likely to include myelitis.
Relation of Visual Function, Retinal Thickness by Optical Coherence Tomography, and MRI Brain Volume in Pediatric-Onset Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
November 2025
Departments of Neurology and Ophthalmology, NYU Grossman School of Medicine, NY; and.
Background And Objectives: While reductions in optical coherence tomography (OCT) pRNFL and ganglion cell-inner plexiform layer thicknesses have been shown to be associated with brain atrophy in adult-onset MS (AOMS) cohorts, the relationship between OCT and brain MRI measures is less established in pediatric-onset MS (POMS). Our aim was to examine the associations of OCT measures with volumetric MRI in a cohort of patients with POMS to determine whether OCT measures reflect CNS neurodegeneration in this patient population, as is seen in AOMS cohorts.
Methods: This was a cross-sectional study with retrospective ascertainment of patients with POMS evaluated at a single center with expertise in POMS and neuro-ophthalmology.
The Number of CD34 Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure.
Clin Transplant
September 2025
Centro De Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico.
Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination.
ACS Chem Neurosci
September 2025
Department of Medical Biology, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
IL-17A is a pro-inflammatory cytokine that significantly contributes to the pathogenesis of autoimmune diseases, including multiple sclerosis (MS). Previous studies have suggested that PARP-1 inhibitors can modulate IL-17A-mediated inflammation, prompting the investigation of Niraparib, an FDA-approved PARP-1 inhibitor, as a potential therapeutic agent for MS. In this study, we hypothesized that Niraparib could disrupt the interaction between IL-17A and its receptor, IL-17RA.
View Article and Find Full Text PDF